VEGFA and age-related macular degeneration: ,3 Rather than correcting for a specific genetic alteration as is done for IRDs, a novel approach for AMD would utilise vector-mediated introduction of a genetic sequence (i.e., biofactory approach) to generate endogenous production of therapeutic proteins targeting well-established pathways, such as vascular endothelial growth factor (VEGF) antagonists.2